Brind.

Cardiff Oncology, a company in the medical/biomedical sector, underperformed the broader market index on July 30, 2025.

1 report, 1 independent Updated Jul 30

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Incepta Pharmaceuticals

Keep exploring

The entities involved

Incepta Pharmaceuticals
incepta
- Tilray Brands, Inc.'s stock change lagged the S&P 500 gain on August 28, 2025, while the company holds a Zacks Rank of #3.Sun 03:24
- Precision BioSciences and Incepta Pharmaceuticals were noted as belonging to a specified industry in August 2025.Sat 20:39

Coverage

Newest first; wire copies grouped

Jul 30ZacksCardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This